ArticleAmerican journal of hematology2008
Elevated urinary leukotriene E4 levels are associated with hospitalization for pain in children with sickle cell disease.
Article in American journal of hematology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 41 citations in OpenAlex.
- Phase 2 trial of montelukast for prevention of pain in sickle cell disease.Blood advances · 2020Trial
- Plasma oxylipins in children with sickle cell disease: Associations with biomarkers of inflammation and endothelial activation.Prostaglandins, leukotrienes, and essential fatty acids · 2025Article
- Mechanisms of pain in sickle cell disease.British journal of pain · 2021Article
- Management of chronic respiratory complications in children and adolescents with sickle cell disease.European respiratory review : an official journal of the European Respiratory Society · 2020Review
- Placenta growth factor mediated gene regulation in sickle cell disease.Blood reviews · 2018Review
- Advances in new drug therapies for the management of sickle cell disease.Expert opinion on orphan drugs · 2018Article
- Article
- Leukotrienes and sex: strange bedfellows?The Journal of clinical investigation · 2017Article
- Placental growth factor: What hematologists need to know.Blood reviews · 2017Review
- Placenta growth factor augments airway hyperresponsiveness via leukotrienes and IL-13.The Journal of clinical investigation · 2016Article
- Inflammatory targets of therapy in sickle cell disease.Translational research : the journal of laboratory and clinical medicine · 2016Review
- Role of biomarkers in understanding and treating children with asthma: towards personalized care.Pharmacogenomics and personalized medicine · 2013Review
- Asthma management in sickle cell disease.BioMed research international · 2013Review
- Markers of severe vaso-occlusive painful episode frequency in children and adolescents with sickle cell anemia.The Journal of pediatrics · 2012Article
- Asthma morbidity and treatment in children with sickle cell disease.Expert review of respiratory medicine · 2011Review
- Article
- Placenta growth factor-induced early growth response 1 (Egr-1) regulates hypoxia-inducible factor-1alpha (HIF-1alpha) in endothelial cells.The Journal of biological chemistry · 2010Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Cysteinyl leukotrienes (CsyLTs) are inflammatory mediators produced by white blood cells. Leukotriene LTE(4) is the stable metabolite of CsyLTs, which can be measured in urine. We tested two hypotheses among children with sickle cell disease (SCD): (1) baseline urinary LTE(4) levels are elevated in children with SCD when compared with controls; and (2) baseline LTE(4) levels are associated with an increased incidence rate of hospitalization for SCD-related pain. Baseline LTE(4) levels were measured in children with SCD (cases) and children without SCD matched for age and ethnicity (controls). Medical records of cases were reviewed to assess the frequency of hospitalization for pain within 3 years of study entry. LTE(4) levels were obtained in 71 cases and 22 controls. LTE(4) levels were higher in cases compared with controls (median LTE(4): 100 vs. 57 pg/mg creatinine, P < 0.001). After adjustment for age and asthma diagnosis, a greater incidence rate of hospitalization for pain was observed among children with SCD in the highest LTE(4) tertile when compared with the lowest (114 vs. 52 episodes per 100 patient-years, P = 0.038). LTE(4) levels are elevated in children with SCD when compared with controls. LTE(4) levels are associated with an increased rate of hospitalizations for pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.